2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Directors’ Report continued REMUNERATION REPORT (AUDITED) (CONTINUED) 46 2011 01 Jan 11 Balance No. Award Date Fair value per option at award Date Non Executive Directors Addison, J.L - - - Clarke, D - - - James, S - - - Webb, S - - - Executive Directors Rosen, H - - - Ogru, E - - - Key Management Personnel Banti, F1 2,650,000 1-Jul-08 $0.096 Gavin, P 400,000 22-May-06 $0.091 100,000 18-Aug-08 $0.053 300,000 18-Jun-09 $0.095 Arnott, A - - - Butala, D 250,000 18-Jun-09 $0.095 Harrison, K - - - Kyriakou, K - - - Libinaki, R 400,000 22-May-06 $0.091 100,000 18-Aug-08 $0.053 150,000 18-Jun-09 $0.095 Totals 4,350,000 - - 1 F Banti is no longer a key management personnel due to his resignation on 29 July 2011, although his options remain exercisable. All options granted to key management personnel have been issued in accordance with the provisions of the Employee Share Option Plan (ESOP). PHOSPHAGENICS ANNUAL REPORT 2012
Exercise Price Expiry Date Net other change No. 31 Dec 11 Balance No. Vested No. - - - - - - - - - - - - 2,400,000 2,400,000 2,400,000 - - - - - - - - - - - - - - - 0.13 30-Jun-18 (2,650,000) - - 0.23 22-May-11 (400,000) - - 0.15 17-Aug-13 - 100,000 100,000 0.15 17-Jun-14 - 300,000 300,000 - - - - - 0.15 17-Jun-14 - 250,000 250,000 - - - - - - - - - - 0.23 22-May-11 (400,000) - - 0.15 17-Aug-13 - 100,000 100,000 0.15 17-Jun-14 - 150,000 150,000 - - (1,050,000) 3,300,000 3,300,000 47 DIRECTOR’S REPORT
Page 1 and 2: 20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4: highlights March... April... May...
Page 5 and 6: 03 Jonathan Addison Chairman & Inde
Page 7 and 8: COLLABORATIONS Strategic Collaborat
Page 9 and 10: The Phosphagenics Evolution THE STO
Page 11 and 12: “ We also reached agreement with
Page 13 and 14: Overview of our opioid development
Page 15 and 16: 13 is branded as Butrans or Norspan
Page 17 and 18: Personal Care ASHLAND INC (FORMERLY
Page 19 and 20: BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22: cellulite contour crème BioElixia
Page 23 and 24: Intellectual Property Title Countri
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47: Exercise Price Expiry Date Net othe
Page 51 and 52: Fair value per performance right at
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74: Application date of standard Impact
Page 99 and 100:
Notes to the consolidated fi nancia
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Independent Auditor’s Report 111
Page 115 and 116:
Additional Shareholder Information
Page 117 and 118:
Additional Shareholder Information
Page 119:
corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

Create successful ePaper yourself

Delete template?

Save as template?